At 144 weeks of treatment, the average change from baseline remained similar in both treatment groups (-3.07 and -3.03 log10 copies/ ml; +263 and +283 cells/ mm3 in the tenofovir disoproxil 245 mg (as fumarate) and stavudine groups, respectively).